42
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effects of Neonatal BCG-Japan Versus BCG-Russia Vaccination on Overall Mortality and Morbidity: Randomized Controlled Trial From Guinea-Bissau (BCGSTRAIN II)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Vaccination with the Danish strain of bacille Calmette-Guérin (BCG) has been associated with pronounced reductions in all-cause neonatal mortality and morbidity. Developing a skin reaction postvaccination is associated with markedly reduced mortality risk. It is unknown whether the beneficial nonspecific effects are maintained across different BCG strains.

          Methods

          This was an open-label randomized controlled trial in Guinea-Bissau, comparing BCG-Japan (n = 8754) versus BCG-Russia (n = 8752) for all-cause hospital admission risk by 6 weeks of age (primary outcome) and 6 months of age. Additional secondary outcomes were in-hospital case-fatality risk (CFR), all-cause mortality, and BCG skin reaction prevalence. Participants were followed through telephone calls at 6 weeks and 6 months, with a subgroup also visited at home. We assessed admission and mortality risk in Cox models providing incidence rate ratios (IRRs) and mortality rate ratios. CFR and skin reactions were assessed by binomial regression providing risk ratios. Analyses were done overall and stratified by sex.

          Results

          BCG strain was not associated with admission risk, the BCG-Japan/BCG-Russia IRR being 0.92 (95% confidence interval [CI], .81–1.05) by 6 weeks and 0.92 (95% CI, .82–1.02) by 6 months. By 6 months of age, there were significantly fewer BCG-Japan infants with no skin reaction (1%) than for BCG-Russia (2%), the risk ratio being 0.36 (95% CI, .16–.81). BCG-Japan skin reactions were also larger.

          Conclusions

          Both vaccines induced a skin reaction in almost all participants. The BCG strains had comparable effects on morbidity and mortality, but BCG-Japan was associated with more and larger skin reactions that are indicators of lower mortality risk.

          Clinical Trials Registration

          NCT03400878.

          Abstract

          In a randomized controlled trial from Guinea-Bissau contrasting BCG-Japan and BCG-Russia, BCG strain was not associated with differences in all-cause morbidity and mortality by 6 weeks or 6 months of age. BCG-Japan produced more and larger BCG skin reactions.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.

          Adaptive features of innate immunity, recently described as "trained immunity," have been documented in plants, invertebrate animals, and mice, but not yet in humans. Here we show that bacille Calmette-Guérin (BCG) vaccination in healthy volunteers led not only to a four- to sevenfold increase in the production of IFN-γ, but also to a twofold enhanced release of monocyte-derived cytokines, such as TNF and IL-1β, in response to unrelated bacterial and fungal pathogens. The enhanced function of circulating monocytes persisted for at least 3 mo after vaccination and was accompanied by increased expression of activation markers such as CD11b and Toll-like receptor 4. These training effects were induced through the NOD2 receptor and mediated by increased histone 3 lysine 4 trimethylation. In experimental studies, BCG vaccination induced T- and B-lymphocyte-independent protection of severe combined immunodeficiency SCID mice from disseminated candidiasis (100% survival in BCG-vaccinated mice vs. 30% in control mice). In conclusion, BCG induces trained immunity and nonspecific protection from infections through epigenetic reprogramming of innate immune cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?

            Observational studies have suggested that BCG may have nonspecific beneficial effects on survival. Low-birth-weight (LBW) children are not given BCG at birth in Guinea-Bissau; we conducted a randomized trial of BCG at birth (early BCG) vs delayed BCG. In the period 2004-2008 we recruited 2320 LBW children in Bissau. The children were visited at home at 2, 6, and 12 months of age. With a pretrial infant mortality of 250 per 1000, we hypothesized a 25% reduction in infant mortality for LBW children. Infant mortality was only 101 per 1000 during the trial. In the primary analysis, infant mortality was reduced insignificantly by 17% (mortality rate ratio [MRR] = .83 [.63-1.08]). In secondary analyses, early BCG vaccine was safe with an MRR of .49 (.21-1.15) after 3 days and .55 (.34-.89) after 4 weeks. The reduction in neonatal mortality was mainly due to fewer cases of neonatal sepsis, respiratory infection, and fever. The impact of early BCG on infant mortality was marked for children weighing <1.5 kg (MRR = .43 [.21-.85]) who had lower coverage for diphtheria-tetanus-pertussis vaccinations. Though early BCG did not reduce infant mortality significantly, it may have a beneficial effect in the neonatal period. This could be important for public health because BCG is often delayed in low-income countries.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              History of BCG Vaccine.

              Tuberculosis (TB) is still responsible for 2 million deaths every year despite being a treatable airborne infectious disease. "Consumption" and "Phthisis" were terms historically used to describe TB, which was responsible for one in four deaths in the 19th century. Due to its infectious nature, chronic progression and long treatment, TB is a great burden for society. Moreover the emergence of multi-drug resistant TB and the current TB-HIV epidemic has raised even greater concern. Treating and preventing TB has become a permanent challange since the ancient times. Bacille Calmette-Guérin (BCG) is the only vaccine available today and has been used for more than 90 years with astonishing safety records. However, its efficacy remains controversial. No universal BCG vaccination policy exists, with some countries merely recommending its use and others that have implemented immunization programs. In this article we review several important milestones of BCG vaccine development from the discovery till today.
                Bookmark

                Author and article information

                Contributors
                Journal
                Open Forum Infect Dis
                Open Forum Infect Dis
                ofid
                Open Forum Infectious Diseases
                Oxford University Press (US )
                2328-8957
                March 2024
                01 February 2024
                01 February 2024
                : 11
                : 3
                : ofae057
                Affiliations
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, Odense Patient Data Explorative Network (OPEN), Department of Clinical Research, University of Southern Denmark and Odense University Hospital , Odense, Denmark
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, Odense Patient Data Explorative Network (OPEN), Department of Clinical Research, University of Southern Denmark and Odense University Hospital , Odense, Denmark
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, INDEPTH Network , Bissau, Guinea-Bissau
                Bandim Health Project, Odense Patient Data Explorative Network (OPEN), Department of Clinical Research, University of Southern Denmark and Odense University Hospital , Odense, Denmark
                Danish Institute of Advanced Study, University of Southern Denmark , Odense, Denmark
                Author notes
                Correspondence: Frederik Schaltz-Buchholzer, MD, PhD, Bandim Health Project, University of Southern Denmark, Studiestræde 6, 1455, Copenhagen, Denmark ( frederik@ 123456bandim.org ); Christine Stabell Benn, DMSc, Bandim Health Project, University of Southern Denmark, Studiestræde 6, 1455 Copenhagen, Denmark ( cbenn@ 123456health.sdu.dk ).

                Potential conflicts of interest. All authors: No reported conflicts.

                Author information
                https://orcid.org/0000-0001-7643-8322
                https://orcid.org/0000-0003-3384-7489
                https://orcid.org/0000-0002-5775-8854
                https://orcid.org/0000-0001-8331-1389
                https://orcid.org/0000-0001-6102-3810
                Article
                ofae057
                10.1093/ofid/ofae057
                10946234
                38500576
                8f044b78-4c42-406d-ae00-86864a049d69
                © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

                History
                : 20 October 2023
                : 24 January 2024
                : 29 January 2024
                : 18 March 2024
                Page count
                Pages: 11
                Funding
                Funded by: University of Southern Denmark, DOI 10.13039/501100006356;
                Funded by: Augustinusfonden;
                Funded by: MICA-Fonden;
                Funded by: Research Center for Vitamins and Vaccines;
                Funded by: Danish National Research Foundation, DOI 10.13039/501100001732;
                Award ID: DNRF108
                Funded by: European and Developing Countries Clinical Trials Partnership, DOI 10.13039/501100001713;
                Award ID: RIA2020EF-3049
                Categories
                Clinical Trials and Therapeutics
                Major Article
                AcademicSubjects/MED00290

                bacille calmette-guérin vaccine,bcg strains,early-life morbidity and mortality,nonspecific effects of vaccines

                Comments

                Comment on this article